Allakos Inc (ALLK)

$1.06

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Allakos Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.8% return, outperforming this stock by 123.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 336.7%

Performance

  • $1.03
    $1.12
    $1.06
    downward going graph

    3.3%

    Downside

    Day's Volatility :8.48%

    Upside

    5.36%

    downward going graph
  • $1.00
    $5.64
    $1.06
    downward going graph

    5.66%

    Downside

    52 Weeks Volatility :82.27%

    Upside

    81.21%

    downward going graph

Returns

PeriodAllakos IncSector (Health Care)Index (Russel 2000)
3 Months
-8.62%
-0.7%
0.0%
6 Months
-44.21%
7.7%
0.0%
1 Year
-75.12%
3.3%
-1.7%
3 Years
-98.99%
13.9%
-20.7%

Highlights

Market Capitalization
93.1M
Book Value
$1.92
Earnings Per Share (EPS)
-2.14
Wall Street Target Price
2.9
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-38.9%
Return On Equity TTM
-77.5%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-189.9M
Diluted Eps TTM
-2.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.2
EPS Estimate Next Year
-0.7
EPS Estimate Current Quarter
-0.47
EPS Estimate Next Quarter
-0.5

Analyst Recommendation

Buy
    66%Buy
    26%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Allakos Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
4
4
5
Sell
1
1
2

Analyst Forecast

What analysts predicted

Upside of 173.58%

Current $1.06
Target $2.90

Technicals Summary

Sell

Neutral

Buy

Allakos Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Allakos Inc
Allakos Inc
-15.2%
-44.21%
-75.12%
-98.99%
-97.18%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Allakos Inc
Allakos Inc
NA
NA
NA
-1.2
-0.77
-0.39
NA
1.92
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Allakos Inc
Allakos Inc
Buy
$93.1M
-97.18%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
410.4%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Institutional Holdings

  • Bvf Inc

    9.73%
  • T. Rowe Price Associates, Inc.

    9.01%
  • NEA Management Company, LLC

    7.00%
  • BlackRock Inc

    5.82%
  • RiverVest Venture Management LLC

    5.68%
  • Citadel Advisors Llc

    4.72%

Corporate Announcements

  • Allakos Inc Earnings

    Allakos Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.

Organization
Allakos Inc
Employees
131
CEO
Dr. Robert Alexander Ph.D.
Industry
Health Technology

FAQs